Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15

Arjan Mofers, Paola Perego, Karthik Selvaraju, Laura Gatti, Joachim Gullbo, Stig Linder, Padraig D’Arcy

Research output: Contribution to journalArticle

Abstract

Background b-AP15/VLX1570 are small molecule inhibitors of the ubiquitin specific peptidase 14 (USP14) and ubiquitin carboxyl-terminal hydrolase 5 (UCHL5) deubiquitinases (DUBs) of the 19S proteasome. b-AP15/VLX1570 have been shown to be cytotoxic to cells resistant to bortezomib, raising the possibility that this class of drugs can be used as a second-line therapy for treatment-resistant multiple myeloma. Limited information is available with regard to potential resistance mechanisms to b-AP15/VLX1570. Results We found that b-AP15-induced cell death is cell-cycle dependent and that non-cycling tumor cells may evade b-AP15-induced cell death. Such non-cycling cells may re-enter the proliferative state to form colonies of drug-sensitive cells. Long-term selection of cells with bAP15 resulted in limited drug resistance (~2-fold) that could be reversed by buthionine sulphoximine, implying altered glutathione (GSH) metabolism as a resistance mechanism. In contrast, drug uptake and overexpression of drug efflux transporters were found not to be associated with b-AP15 resistance. Conclusions The proteasome DUB inhibitors b-AP15/VLX1570 are cell cycle-active. The slow and incomplete development of resistance towards these compounds is an attractive feature in view of future clinical use.

Original languageEnglish
Article numbere0223807
JournalPLoS One
Volume14
Issue number10
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

drugs
Molecules
proteasome endopeptidase complex
ubiquitin
resistance mechanisms
Pharmaceutical Preparations
Cells
cell death
Cell death
Proteasome Endopeptidase Complex
cell cycle
Ubiquitin
cells
Cell Cycle
Cell Death
myeloma
peptidases
Buthionine Sulfoximine
drug resistance
hydrolases

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15. / Mofers, Arjan; Perego, Paola; Selvaraju, Karthik; Gatti, Laura; Gullbo, Joachim; Linder, Stig; D’Arcy, Padraig.

In: PLoS One, Vol. 14, No. 10, e0223807, 01.01.2019.

Research output: Contribution to journalArticle

Mofers, Arjan ; Perego, Paola ; Selvaraju, Karthik ; Gatti, Laura ; Gullbo, Joachim ; Linder, Stig ; D’Arcy, Padraig. / Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15. In: PLoS One. 2019 ; Vol. 14, No. 10.
@article{1952ec88740a44ebaaaf546730baad39,
title = "Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15",
abstract = "Background b-AP15/VLX1570 are small molecule inhibitors of the ubiquitin specific peptidase 14 (USP14) and ubiquitin carboxyl-terminal hydrolase 5 (UCHL5) deubiquitinases (DUBs) of the 19S proteasome. b-AP15/VLX1570 have been shown to be cytotoxic to cells resistant to bortezomib, raising the possibility that this class of drugs can be used as a second-line therapy for treatment-resistant multiple myeloma. Limited information is available with regard to potential resistance mechanisms to b-AP15/VLX1570. Results We found that b-AP15-induced cell death is cell-cycle dependent and that non-cycling tumor cells may evade b-AP15-induced cell death. Such non-cycling cells may re-enter the proliferative state to form colonies of drug-sensitive cells. Long-term selection of cells with bAP15 resulted in limited drug resistance (~2-fold) that could be reversed by buthionine sulphoximine, implying altered glutathione (GSH) metabolism as a resistance mechanism. In contrast, drug uptake and overexpression of drug efflux transporters were found not to be associated with b-AP15 resistance. Conclusions The proteasome DUB inhibitors b-AP15/VLX1570 are cell cycle-active. The slow and incomplete development of resistance towards these compounds is an attractive feature in view of future clinical use.",
author = "Arjan Mofers and Paola Perego and Karthik Selvaraju and Laura Gatti and Joachim Gullbo and Stig Linder and Padraig D’Arcy",
year = "2019",
month = "1",
day = "1",
doi = "10.1371/journal.pone.0223807",
language = "English",
volume = "14",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

TY - JOUR

T1 - Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15

AU - Mofers, Arjan

AU - Perego, Paola

AU - Selvaraju, Karthik

AU - Gatti, Laura

AU - Gullbo, Joachim

AU - Linder, Stig

AU - D’Arcy, Padraig

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background b-AP15/VLX1570 are small molecule inhibitors of the ubiquitin specific peptidase 14 (USP14) and ubiquitin carboxyl-terminal hydrolase 5 (UCHL5) deubiquitinases (DUBs) of the 19S proteasome. b-AP15/VLX1570 have been shown to be cytotoxic to cells resistant to bortezomib, raising the possibility that this class of drugs can be used as a second-line therapy for treatment-resistant multiple myeloma. Limited information is available with regard to potential resistance mechanisms to b-AP15/VLX1570. Results We found that b-AP15-induced cell death is cell-cycle dependent and that non-cycling tumor cells may evade b-AP15-induced cell death. Such non-cycling cells may re-enter the proliferative state to form colonies of drug-sensitive cells. Long-term selection of cells with bAP15 resulted in limited drug resistance (~2-fold) that could be reversed by buthionine sulphoximine, implying altered glutathione (GSH) metabolism as a resistance mechanism. In contrast, drug uptake and overexpression of drug efflux transporters were found not to be associated with b-AP15 resistance. Conclusions The proteasome DUB inhibitors b-AP15/VLX1570 are cell cycle-active. The slow and incomplete development of resistance towards these compounds is an attractive feature in view of future clinical use.

AB - Background b-AP15/VLX1570 are small molecule inhibitors of the ubiquitin specific peptidase 14 (USP14) and ubiquitin carboxyl-terminal hydrolase 5 (UCHL5) deubiquitinases (DUBs) of the 19S proteasome. b-AP15/VLX1570 have been shown to be cytotoxic to cells resistant to bortezomib, raising the possibility that this class of drugs can be used as a second-line therapy for treatment-resistant multiple myeloma. Limited information is available with regard to potential resistance mechanisms to b-AP15/VLX1570. Results We found that b-AP15-induced cell death is cell-cycle dependent and that non-cycling tumor cells may evade b-AP15-induced cell death. Such non-cycling cells may re-enter the proliferative state to form colonies of drug-sensitive cells. Long-term selection of cells with bAP15 resulted in limited drug resistance (~2-fold) that could be reversed by buthionine sulphoximine, implying altered glutathione (GSH) metabolism as a resistance mechanism. In contrast, drug uptake and overexpression of drug efflux transporters were found not to be associated with b-AP15 resistance. Conclusions The proteasome DUB inhibitors b-AP15/VLX1570 are cell cycle-active. The slow and incomplete development of resistance towards these compounds is an attractive feature in view of future clinical use.

UR - http://www.scopus.com/inward/record.url?scp=85073722979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073722979&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0223807

DO - 10.1371/journal.pone.0223807

M3 - Article

C2 - 31639138

AN - SCOPUS:85073722979

VL - 14

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

M1 - e0223807

ER -